LinkedIn operates a professional networking platform that connects professionals worldwide, enabling career development, business connections, and professional content sharing.

LinkedIn

Umoja Biopharma develops integrated platform therapeutics that reprogram the immune system to target cancer cells and generate lasting remissions.

Umoja Biopharma

Li Lab of Computational Cancer Immunology focuses on cancer research, particularly on the computational analysis of immune responses in cancer. The lab has conducted various studies related to T cell receptor repertoires, mitochondrial transfer between cells, and cancer immunotherapy.

Metric
Company Name	LinkedIn	Umoja Biopharma	Li Lab of Computational Cancer Immunology
Symbol
MSH ID	COM:ONCOMYX	COM:UMOJA-BIOPHARMA	ORG:LILAB-UTSW
Market	PRIVATE	PRIVATE	PRIVATE
Sector	Technology	Healthcare & Health Services	Healthcare & Health Services
Industry	Professional Social Networking	Biotechnology	Biotechnology
Country	US	US	US
Stage
Employee Count
Website	oncomyx.com	umoja-biopharma.com	lilab-utsw.org
LinkedIn
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic		6.83K
Web Traffic Growth		-0.19
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

ONCO

COM:ONCOMYX

LinkedIn

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue